Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma

Endocrine-Related Cancer

Volumn 18, Issue 6, 2011, Pages 783-792

  Végran, Frédérique ^a   Boidot, Romain ^a   Bonnetain, Franck ^a   Cadouot, Muriel ^a   Chevrier, Sandy ^a   Lizard Nacol, Sarab ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; SURVIVIN; SURVIVIN 3B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; SIGNATURE GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855928566     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0105     Document Type: Article

References (20)

1. Altieri DC 2008 Survivin, cancer networks and pathway-directed drug discovery. Nature Reviews Cancer 8 61-70. (doi:10.1038/nrc2293)
2. Ambrosini G, Adida C & Altieri DC 1997 A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine 3 917-921. (doi:10.1038/nm0897-917)
3. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T & Inuzuka M 2004 Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochemical and Biophysical Research Communications 314 902-907. (doi:10.1016/j.bbrc.2003.12.178)
4. Boidot R, Végran F, Soubeyrand MS, Fumoleau P, Coudert B & Lizard-Nacol S 2009 Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma. Cancer Investigation 27 521-528. (doi:10.1080/07357900802298096)
5. Bria E, Visca P, Novelli F, Casini B, Diodoro MG, Perrone-Donnorso R, Botti C, Sperduti I, Facciolo F, Milella M et al. 2008 Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. European Journal of Surgical Oncology 34 593-598. (doi:10.1016/j.ejso.2007.06.002)
6. Caldas H, Honsey LE & Altura RA 2005 Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Molecular Cancer 4 11. (doi:10.1186/1476-4598-4-11)
7. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF & Wan DS 2009 Elevated expression of MMP7, TROP2, and survivin are associated with survival disease recurrence, and liver metastasis of colon cancer. International Journal of Colorectal Diagnosis 24 875-884. (doi:10.1007/s00384-009-0725-z)
8. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rödel F, Klein-Hitpass L, Kovács AF, Döring C, Hansmann ML et al. 2007 The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 6 1502-1509.
9. Krieg A, Mahotka C, Krieg T, Grabsch H, Müller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE & Gerharz CD 2002 Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. British Journal of Cancer 86 737-743. (doi:10.1038/sj.bjc. 6600153)
10. Livak KJ & Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 402-408. (doi:10.1006/meth.2001.1262)
11. Mahotka C, Wenzel M, Springer E, Gabbert HE & Gerharz CD 1999 Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Research 59 6097-6102.
12. O'Driscoll L, Linehan R & Clynes M 2003 Survivin role in normal and in pathological conditions. Current Cancer Drug Targets 2 131-152. (doi:10.2174/1568009033482038)
13. Roca H, Varsos Z & Pienta KJ 2008 CCL2 protects prostate PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. Journal of Biological Chemistry 283 25057-25073. (doi:10.1074/jbc.M801073200)
14. Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill ADK, McDermott E, O'Higgins N & Duffy MJ 2005 Expression of Survivin and its splice variants Survivin-2B and Survivin-ΔEx3 in breast cancer. British Journal of Cancer 92 120-124. (doi:10.1038/sj.bjc.6602314)
15. Span PN, Tjan-Heijnen VC, Heuvel JJ, de Kok JB, Foekens JA & Sweep FC 2006 Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clinical Chemistry 52 1693-1700. (doi:10.1373/clinchem.2006.071613)
16. Tonini G, Vincenzi B, Santini D, Scarpa S, Vasaturo T, Malacrino C, Coppola R, Magistrelli P, Borzomati D, Baldi A et al. 2005 Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. British Journal of Cancer 92 2225-3222. (doi:10.1038/sj.bjc.6602632)
17. Végran F, Boidot R, Oudin C, Riedinger JM & Lizard-Nacol S 2005 Distinct expression of Survivin splice variants in breast cancinomas. International Journal of Oncology 27 1151-1157.
18. Végran F, Boidot R, Oudin C, Defrain C, Rebucci M &Lizard-Nacol S 2007 Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 26 290-297. (doi:10.1038/sj.onc.1209784)
19. Yang D, Welm A & Bishop M 2004 Cell division and cell survival in the absence of survivin. PNAS 101 15100-15105. (doi:10.1073/pnas.0406665101)
20. Zhu N, Gu L, Findley HW, Li F & Zhou M 2004 An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23 7545-7551. (doi:10.1038/sj.onc.1208038)